Homo sapiens Protein: PIM1 | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Summary | |||||||||||||||||||||||
InnateDB Protein | IDBP-85490.6 | ||||||||||||||||||||||
Last Modified | 2014-10-13 [Report errors or provide feedback] | ||||||||||||||||||||||
Gene Symbol | PIM1 | ||||||||||||||||||||||
Protein Name | pim-1 oncogene | ||||||||||||||||||||||
Synonyms | PIM; | ||||||||||||||||||||||
Species | Homo sapiens | ||||||||||||||||||||||
Ensembl Protein | ENSP00000362608 | ||||||||||||||||||||||
InnateDB Gene | IDBG-85488 (PIM1) | ||||||||||||||||||||||
Protein Structure | |||||||||||||||||||||||
UniProt Annotation | |||||||||||||||||||||||
Function | Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl- X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post- translational levels. Phosphorylation of CDKN1B,induces 14-3-3- proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. {ECO:0000269PubMed:10664448, ECO:0000269PubMed:12431783, ECO:0000269PubMed:15528381, ECO:0000269PubMed:16356754, ECO:0000269PubMed:1825810, ECO:0000269PubMed:18593906, ECO:0000269PubMed:19749799}. | ||||||||||||||||||||||
Subcellular Localization | Isoform 2: Cytoplasm. Nucleus.Isoform 1: Cell membrane. | ||||||||||||||||||||||
Disease Associations | |||||||||||||||||||||||
Tissue Specificity | Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines. {ECO:0000269PubMed:16186805}. | ||||||||||||||||||||||
Comments | |||||||||||||||||||||||
Interactions | |||||||||||||||||||||||
Number of Interactions |
This gene and/or its encoded proteins are associated with 44 experimentally validated interaction(s) in this database.
They are also associated with 2 interaction(s) predicted by orthology.
|
||||||||||||||||||||||
Gene Ontology | |||||||||||||||||||||||
Molecular Function |
|
||||||||||||||||||||||
Biological Process |
|
||||||||||||||||||||||
Cellular Component |
|
||||||||||||||||||||||
Protein Structure and Domains | |||||||||||||||||||||||
PDB ID | |||||||||||||||||||||||
InterPro |
IPR000719
Protein kinase domain IPR001245 Serine-threonine/tyrosine-protein kinase catalytic domain IPR002290 Serine/threonine/dual specificity protein kinase, catalytic domain IPR010440 Lipopolysaccharide kinase IPR011009 Protein kinase-like domain IPR020635 Tyrosine-protein kinase, catalytic domain |
||||||||||||||||||||||
PFAM |
PF00069
PF07714 PF06293 |
||||||||||||||||||||||
PRINTS |
PR00109
|
||||||||||||||||||||||
PIRSF | |||||||||||||||||||||||
SMART |
SM00220
SM00219 |
||||||||||||||||||||||
TIGRFAMs | |||||||||||||||||||||||
Post-translational Modifications | |||||||||||||||||||||||
Modification | |||||||||||||||||||||||
Cross-References | |||||||||||||||||||||||
SwissProt | P11309 | ||||||||||||||||||||||
PhosphoSite | PhosphoSite-P11309 | ||||||||||||||||||||||
TrEMBL | A0A024RD25 | ||||||||||||||||||||||
UniProt Splice Variant | |||||||||||||||||||||||
Entrez Gene | 5292 | ||||||||||||||||||||||
UniGene | Hs.81170 | ||||||||||||||||||||||
RefSeq | NP_002639 | ||||||||||||||||||||||
HUGO | HGNC:8986 | ||||||||||||||||||||||
OMIM | 164960 | ||||||||||||||||||||||
CCDS | CCDS4830 | ||||||||||||||||||||||
HPRD | 01292 | ||||||||||||||||||||||
IMGT | |||||||||||||||||||||||
EMBL | AF386792 AL353579 BC020224 CH471081 DQ022562 M16750 M24779 M27903 M54915 | ||||||||||||||||||||||
GenPept | AAA36447 AAA60089 AAA60090 AAA81553 AAH20224 AAK70871 AAY87461 CAI20316 EAX03934 EAX03935 | ||||||||||||||||||||||